Journal of Family Medicine and Primary Care (Jan 2022)

Serological prevalence of SARS-CoV-2 antibody among children and young age group (between 2 and 17 years) in India: An interim result from a large multicentric population-based seroepidemiological study

  • Puneet Misra,
  • Shashi Kant,
  • Randeep Guleria,
  • Sanjay K Rai,
  • Surekha Kishore,
  • Subrata Baidya,
  • Arvind Kumar Singh,
  • Palanivel Chinnakali,
  • Guruprasad R Medigeshi,
  • Pradeep Kumar Chaturvedi,
  • Hari Shanker Joshi,
  • Suprakash Mandal,
  • Meenu Sangral,
  • Kapil Yadav,
  • Mohan Bairwa,
  • Partha Haldar,
  • Priyanka Kardam,
  • Sharanabasava Patil,
  • Shreya Jha

DOI
https://doi.org/10.4103/jfmpc.jfmpc_2274_21
Journal volume & issue
Vol. 11, no. 6
pp. 2816 – 2823

Abstract

Read online

Background: Estimating seroepidemiolgical prevalence of SARS-CoV-2 antibody is an essential public health strategy. There is insufficient evidence of prevalence among those belonging to young age population in India. Objective: To compare the SARS-CoV-2 seropositivity rate between children and adults in selected sites from India. Materials and Methods: This was a multicentric population-based seroepidemiological study conducted in selected urban and rural areas of five sites selected from four states (Delhi, Odisha, Uttar Pradesh, Tripura) of India. Participants aged ≥1 year were included from different clusters of each area. Total serum antibody against SARS-CoV-2 virus was assessed qualitatively by using a standard enzyme-linked immunosorbent assay (ELISA) kit.Results: Data collection period was from 15 March 2021 to 10 June 2021. Total available data was of 4509 participants, of whom 700 were <18 years of age and 3809 were ≥18 years of age. The site-wise number of available data among those aged 2–17 years was 92, 189, 165, 146 and 108 for the sites of Delhi urban, Delhi rural, Bhubaneswar rural, Gorakhpur rural and Agartala rural area, respectively. The seroprevalence was 55.7% in the <18 years age group and 63.5% in the ≥18 years age group. The prevalence among female children was 58% and among male children was 53%. Conclusion: SARS-CoV-2 seropositivity rate among children was high and comparable to that of the adult population. Hence, it is unlikely that any future third wave by prevailing SARS-CoV-2 variant would disproportionately infect children 2 years or older.

Keywords